Further studies with larger patient populations are required to confirm the influence of KIR ligand status on the generated specific adaptive NK cells (with single KIR expression) for the clinical targeting of cancer across HLA barriers in cell therapy. This evidence concerns the gene KIR3DL1 and cancer.